Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study
暂无分享,去创建一个
Ignacio Conget | Andrew Phillips | Esteban Martínez | A. Mocroft | J. Gatell | A. Phillips | J. Blanch | J. Mallolas | E. Martinez | J. Blanco | I. Conget | Amanda Mocroft | José M Gatell | Luis Bianchi | Jordi Blanch | Miguel A García-Viejo | José B Pérez-Cuevas | José L Blanco | José Mallolas | M. García-Viejo | L. Bianchi | J. Pérez-Cuevas
[1] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[2] O. Rouvière,et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study , 2000, AIDS.
[3] M. Cerqueira,et al. Body fat distribution in healthy young and older men. , 1990, Journal of gerontology.
[4] D. Cooper,et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.
[5] A. Mocroft,et al. Changes in use of antiretroviral therapy in regions of Europe over time , 1998, AIDS.
[6] M. Flynn,et al. Total body potassium in aging humans: a longitudinal study. , 1989, The American journal of clinical nutrition.
[7] C. Grunfeld,et al. Fat distribution and metabolic changes in patients with HIV infection. , 1999, AIDS.
[8] C. Moore,et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection , 2000, AIDS.
[9] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[10] R. Schulz,et al. Psychiatric and physical morbidity effects of caregiving. , 1990, Journal of gerontology.
[11] S. Grinspoon,et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. , 1999, The Journal of clinical endocrinology and metabolism.
[12] F. Carrat,et al. Effect of indinavir on HIV‐related wasting , 1998, AIDS.
[13] J. Tobin,et al. Studies in the distribution of body fat: I. Effects of age, sex, and obesity. , 1989, Journal of gerontology.
[14] J. Mallolas,et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] P. Reiss,et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.
[16] E. Martinez,et al. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. , 1999, Current opinion in infectious diseases.
[17] J. Wang,et al. Studies of body composition and fat distribution in HIV-infected and control subjects. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[18] K. Tashima,et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). , 1999, Journal of acquired immune deficiency syndromes.
[19] J. Gatell,et al. Sonographic assessment of regional fat in HIV-1-infected people , 2000, The Lancet.
[20] A. Schindl,et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. , 1999, AIDS.
[21] D. Cooper,et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.
[22] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[23] D. Spiegelman,et al. The effect of protease inhibitors on weight and body composition in HIV‐infected patients , 1998, AIDS.
[24] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[25] J. Gatell,et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.
[26] M. Moroni,et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. , 1999, AIDS.
[27] O. Rouvière,et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. , 1999, AIDS.
[28] K. Miller,et al. Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.